We can’t show the full text here under this license. Use the link below to read it at the source.
Targeting MARCO in combination with anti-CTLA-4 leads to enhanced melanoma regression and immune cell infiltration via macrophage reprogramming
Blocking MARCO and CTLA-4 together may improve melanoma shrinkage and immune cell response by changing macrophage behavior
AI simplified
Abstract
ED31 enhanced the antitumor efficacy of anti-CTLA-4 in C57BL/6J mice bearing B16F10 or Pan02 tumors.
- The combination of ED31 with anti-CTLA-4 significantly increased immune cell infiltration in the .
- Mature conventional dendritic cell recruitment was notably enhanced by the addition of ED31 to anti-CTLA-4 treatment.
- A shift to M1-pattern chemokines produced by macrophages was observed when ED31 was combined with anti-CTLA-4.
- Depleting macrophages eliminated the increased immune cell infiltration and chemokine production, as well as the antitumor efficacy of the therapy.
- Targeting MARCO may improve the effectiveness of anti-CTLA-4 therapy through the reprogramming of macrophages rather than their depletion.
AI simplified
Key numbers
10 cells/cm
Increase in immune cell density
Total immune cells (CD45) density in the after treatment with ED31 and anti-CTLA-4.
n=35 (αCTLA-4+ED31) vs. n=15 (αCTLA-4 alone)
Survival comparison
Survival outcomes in mice treated with ED31 and anti-CTLA-4 versus anti-CTLA-4 alone.